Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

29

Revenue 2017

Soliris

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

Assessing drugs for ultra-rare conditions in the UK

Assessing drugs for ultra-rare conditions in the UK Along the way Soliris underwent review by the now-defunct Advisory Group for National Specialised Services (AGNSS). ... Nevertheless, if it needed convincing about Soliris' cost, NICE was impressed with the drug's benefits.

NICE set to back Alexion's costly 'ultra-orphan' drug

NICE set to back Alexion's costly 'ultra-orphan' drug on high cost drugs - and Soliris' price has previously been a problem for NICE. ... Alexion estimated Soliris produced 25.22 additional QALYs per patient compared with standard care.

Alexion convinces NICE of Soliris' value

Alexion convinces NICE of Soliris' value Alexion's high cost rare disease drug Soliris has been recommended by NICE for use in England under its new approach to highly specialised technologies. ... Soliris (eculizumab) is licensed to treat atypical hemolyic uremic syndrome (aHUS) drug, a

NICE and ‘ultra orphans’

NICE and ‘ultra orphans’ NICE expects to issue its guidance on Soliris by July 2014 and in the meantime NHS England will continue to fund the drug's use for new and existing aHUS patients. ... Soliris remains the only drug so far to be put through NICE's highly specialised

NICE: Alexion must justify Soliris' high cost

NICE: Alexion must justify Soliris' high cost At current disease levels the total NHS spend on Soliris (eculizumab) would be £58m in the first year, rising to £80m over five years at predicted diagnosis rates. ... In its response, Alexion said it was “pleased” that NICE has reaffirmed the

[ Previous 5 results ] 1 2 3 4 5 6 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics